• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SC 13G/A filed by Sangamo Therapeutics Inc.

    11/12/24 4:53:35 PM ET
    $SGMO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $SGMO alert in real time by email
    SC 13G/A 1 UnitedStates_13G__SangamoThe.txt 240.13d-102 Schedule 13G - Information to be included in statements filed pursuant to 240.13d-1(b), (c), and (d) and amendments thereto filed pursuant to 240.13d-2. Securities and Exchange Commission, Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No. 8)* (Name of Issuer) Sangamo Therapeutics Inc (Title of Class of Securities) Common Stock (CUSIP Number) 800677106 (Date of Event Which Requires Filing of this Statement) September 30, 2024 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: X Rule 13d-1(b) Rule 13d-1(c) Rule 13d-1(d) *The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, an* d for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page. The information required in the remainder of this cover page shall not be deemed to be filed for the purpose of Section 18 of the Securities Exchange Act of 1934 ( Act ) or otherwise subject to the liabilities of that section of * the Act but shall be subject to all other provisions of the Act (however, see the Notes). CUSIP No. 800677106 (1) Names of reporting persons The Vanguard Group (2) Check the appropriate box if a member of a group (a) (see instructions) (b) X (3) SEC use only (4) Citizenship or place of organization Pennsylvania Number of shares beneficially owned by each reporting person with: (5) Sole voting power 0 (6) Shared voting power 0 (7) Sole dispositive power 9,543,288 (8) Shared dispositive power 54,354 (9) Aggregate amount beneficially owned by each reporting person 9,597,642 (10) Check if the aggregate amount in Row (9) excludes certain shares (see instructions) (11) Percent of class represented by amount in Row (9) 4.60% (12) Type of reporting person (see instructions) IA Item 1(a) Name of issuer: Sangamo Therapeutics Inc Item 1(b) Address of issuer's principal executive offices: 501 Canal Boulevard Richmond, CA 94084 Items 2(a)-2(c). Name, Address Of principal business office, and Citizenship of* persons filing: The Vanguard Group - 23-1945930 100 Vanguard Blvd. Malvern, PA 19355 2(d) Title of class of securities: Common Stock 2(e) CUSIP Number: 800677106 Item 3. This statement is being filed pursuant to Rule 13d-1. An investment adviser in accordance with 240.13d-1(b)(1)(ii)(E). Item 4. Ownership As of the close of business on September 30, 2024: (a) Aggregate amount beneficially owned: 9,597,642 (b) Percent of class: 4.60% (c) Number of shares as to which person has: 1. The Vanguard Group (a) Amount beneficially owned: 9,597,642 (b) Percent of class: 4.60% (c) Number of shares as to which the person has: (i) Sole power to vote or to direct the vote: 0 (ii) Shared power to vote or to direct the vote: 0 (iii) Sole power to dispose or to direct the disposition of: 9,543,288 (iv) Shared power to dispose or to direct the disposition of: 54,354 Item 5.Ownership of 5 Percent or Less of a Class. If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than 5 percent of the class of securities, check the following . Item 6. Ownership of More than 5 Percent on Behalf of Another Person. The Vanguard Group, Inc.'s clients, including investment companies registered u* nder the Investment Company Act of 1940 and other managed accounts, have the ri* ght to receive or the power to direct the receipt of dividends from, or the pro* ceeds from the sale of, the securities reported herein. No one other person's interest in the securities reported herein is more than 5* %. Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reporting on by the Parent Holding Company or Control Person. Not applicable Item 8. Identification and Classification of Members of the Group Not applicable Item 9. Notice of Dissolution of Group. Not applicable Item 10. Certifications By signing below I certify that, to the best of his/her knowledge and belief, t* he securities referred to above were not acquired and are not held for the pur* pose of or with the effect of changing or influencing the control of the issuer* of the securities and were not acquired and are not held in connection with or* as a participant in any transaction having that purpose or effect. Signature. After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct. Dated: November 12, 2024 THE VANGUARD GROUP By: /s/ Ashley Grim Name: Ashley Grim Title: Head of Global Fund Administration
    Get the next $SGMO alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $SGMO

    DatePrice TargetRatingAnalyst
    12/13/2024$7.00Hold → Buy
    Truist
    12/10/2024$10.00Buy
    H.C. Wainwright
    11/3/2023$6.00 → $2.00Outperform → Sector Perform
    RBC Capital Mkts
    4/28/2023$5.00 → $1.50Neutral → Underperform
    BofA Securities
    2/27/2023$16.00Neutral → Outperform
    Wedbush
    1/6/2023$8.00 → $5.00Buy → Neutral
    BofA Securities
    6/13/2022$5.00Neutral
    Wedbush
    More analyst ratings

    $SGMO
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Sangamo Therapeutics upgraded by Truist with a new price target

      Truist upgraded Sangamo Therapeutics from Hold to Buy and set a new price target of $7.00

      12/13/24 8:18:20 AM ET
      $SGMO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • H.C. Wainwright reiterated coverage on Sangamo Therapeutics with a new price target

      H.C. Wainwright reiterated coverage of Sangamo Therapeutics with a rating of Buy and set a new price target of $10.00

      12/10/24 11:58:57 AM ET
      $SGMO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Sangamo Therapeutics downgraded by RBC Capital Mkts with a new price target

      RBC Capital Mkts downgraded Sangamo Therapeutics from Outperform to Sector Perform and set a new price target of $2.00 from $6.00 previously

      11/3/23 7:45:03 AM ET
      $SGMO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $SGMO
    SEC Filings

    See more
    • SEC Form 424B5 filed by Sangamo Therapeutics Inc.

      424B5 - SANGAMO THERAPEUTICS, INC (0001001233) (Filer)

      5/13/25 5:23:12 PM ET
      $SGMO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Sangamo Therapeutics Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

      8-K - SANGAMO THERAPEUTICS, INC (0001001233) (Filer)

      5/13/25 5:21:19 PM ET
      $SGMO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: SEC Form SCHEDULE 13G/A filed by Sangamo Therapeutics Inc.

      SCHEDULE 13G/A - SANGAMO THERAPEUTICS, INC (0001001233) (Subject)

      5/12/25 5:32:23 PM ET
      $SGMO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $SGMO
    Financials

    Live finance-specific insights

    See more
    • Sangamo Therapeutics Postpones First Quarter 2025 Conference Call to Later the Same Day

      Sangamo Therapeutics, Inc. (NASDAQ:SGMO), a genomic medicine company, today announced that the first quarter earnings call originally scheduled for 4:30p.m. Eastern on Monday, May 12 will be postponed to 6:30p.m. Eastern on Monday, May 12, 2025. The registration and access link previously provided remains the same. Participants should register for, and access, the call using this link. While not required, it is recommended to join 10 minutes prior to the event start. Once registered, participants will be given the option to either dial into the call with the number and unique passcode provided, or to use the dial-out option to connect their phone instantly. The link to access the live web

      5/12/25 4:00:00 PM ET
      $SGMO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Sangamo Therapeutics Announces First Quarter 2025 Earnings Call

      Sangamo Therapeutics, Inc. (NASDAQ:SGMO), a genomic medicine company, today announced that the company has scheduled the release of its first quarter 2025 financial results after the markets close on Monday, May 12, 2025. The company will hold a conference call at 4:30 p.m. Eastern on Monday, May 12, which will remain open to the public. During the conference call, the company will review its financial results and provide business updates. Participants should register for, and access, the call using this link. While not required, it is recommended to join 10 minutes prior to the event start. Once registered, participants will be given the option to either dial into the call with the numbe

      5/6/25 4:35:00 PM ET
      $SGMO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Sangamo Therapeutics Reports Recent Business Highlights and Fourth Quarter and Full Year 2024 Financial Results

      Continued to advance our prioritized neurology genomic medicine pipeline towards the clinic. Announced two neurology license agreements with blue-chip pharma companies, including a global epigenetic regulation and capsid delivery license agreement with Genentech in August 2024 to develop novel genomic medicines for neurodegenerative diseases and a capsid license agreement with Astellas in December 2024 to deliver genomic medicines for up to five neurological disease targets. Raised over $100 million in funding in 2024 through non-dilutive license fees and milestone payments, as well as equity financing. Investigational new drug (IND) application cleared by U.S. Food and Drug Administrati

      3/17/25 4:01:00 PM ET
      $SGMO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $SGMO
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Sangamo Therapeutics Reports Recent Business Highlights and First Quarter 2025 Financial Results

      Announced capsid license agreement with Lilly to deliver genomic medicines for up to five central nervous system (CNS) disease targets. Received $18 million upfront license fee for first target and eligible to earn up to $1.4 billion in additional licensed target fees and milestone payments, plus tiered royalties on potential net sales. Announced derisking milestones in pathway to anticipated biologics license application (BLA) submission for isaralgagene civaparvovec in Fabry disease, including all patients having passed one-year milestone required by U.S. Food and Drug Administration (FDA) for Accelerated Approval regulatory pathway, and productive Type B Chemistry, Manufacturing and Con

      5/12/25 6:26:00 PM ET
      $SGMO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Sangamo Therapeutics Announces Pricing of $23.0 Million Underwritten Offering

      Sangamo Therapeutics, Inc. (NASDAQ:SGMO), a genomic medicine company, today announced the pricing of an underwritten offering consisting of 12,235,000 shares of its common stock and pre-funded warrants to purchase 34,398,393 shares of its common stock, together with accompanying warrants to purchase 46,633,393 shares of its common stock. The combined offering price of each share of common stock and accompanying warrant is $0.50. The combined offering price of each pre-funded warrant and accompanying warrant is $0.49. The common stock and pre-funded warrants are being sold in combination with an accompanying warrant to purchase one share of common stock issued for each share of common stock

      5/12/25 6:23:00 PM ET
      $SGMO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Sangamo Therapeutics Postpones First Quarter 2025 Conference Call to Later the Same Day

      Sangamo Therapeutics, Inc. (NASDAQ:SGMO), a genomic medicine company, today announced that the first quarter earnings call originally scheduled for 4:30p.m. Eastern on Monday, May 12 will be postponed to 6:30p.m. Eastern on Monday, May 12, 2025. The registration and access link previously provided remains the same. Participants should register for, and access, the call using this link. While not required, it is recommended to join 10 minutes prior to the event start. Once registered, participants will be given the option to either dial into the call with the number and unique passcode provided, or to use the dial-out option to connect their phone instantly. The link to access the live web

      5/12/25 4:00:00 PM ET
      $SGMO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $SGMO
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more

    $SGMO
    Leadership Updates

    Live Leadership Updates

    See more
    • PRESIDENT, CEO AND DIRECTOR Macrae Sandy covered exercise/tax liability with 7,488 shares, decreasing direct ownership by 0.32% to 2,318,410 units (SEC Form 4)

      4 - SANGAMO THERAPEUTICS, INC (0001001233) (Issuer)

      5/28/25 4:05:05 PM ET
      $SGMO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SVP, CHIEF LEGAL OFFICER, SECY Willoughby Scott B. covered exercise/tax liability with 1,433 shares, decreasing direct ownership by 0.18% to 781,543 units (SEC Form 4)

      4 - SANGAMO THERAPEUTICS, INC (0001001233) (Issuer)

      5/28/25 4:05:11 PM ET
      $SGMO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SVP, CHIEF FINANCIAL OFFICER Duraibabu Prathyusha covered exercise/tax liability with 1,792 shares, decreasing direct ownership by 0.23% to 778,145 units (SEC Form 4)

      4 - SANGAMO THERAPEUTICS, INC (0001001233) (Issuer)

      5/28/25 4:05:08 PM ET
      $SGMO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Sangamo Therapeutics Announces Appointment of Lisa Rojkjaer, M.D., as Chief Medical Officer

      Sangamo Therapeutics, Inc. (NASDAQ:SGMO), a genomic medicine company, today announced the appointment of Lisa Rojkjaer, M.D., as Chief Medical Officer. She will serve on the Executive Leadership team and report to Nathalie Dubois-Stringfellow, Sangamo's Chief Development Officer. Dr Rojkjaer succeeds Bettina Cockroft, M.D., M.B.A, who is leaving the company to pursue other opportunities. We thank her for her contributions. "We are thrilled to welcome Dr. Rojkjaer, an experienced physician, drug developer, and regulatory expert, to the Sangamo team," said Nathalie Dubois-Stringfellow, Chief Development Officer at Sangamo. "Her deep industry experience across all stages of clinical developm

      5/16/23 8:00:00 AM ET
      $SGMO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Organogenesis Appoints Prathyusha Duraibabu to Board of Directors

      CANTON, Mass., Nov. 22, 2021 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (NASDAQ:ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical & Sports Medicine markets, today announced the appointment of Prathyusha Duraibabu to the Company's Board of Directors, effective November 19, 2021. Ms. Duraibabu will serve as an independent director of the Company and member of the Audit Committee of the Board. "Prathyusha is a proven leader who brings significant expertise from a more than 24-year career in the technology and healthcare sectors, and has held senior leadership positio

      11/22/21 7:00:00 AM ET
      $ORGO
      $PACB
      $SGMO
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Sangamo Therapeutics Appoints Prathyusha Duraibabu, CPA, MBA, to Chief Financial Officer

      Sangamo Therapeutics, Inc. (NASDAQ:SGMO), a genomic medicine company, announced today the appointment of Prathyusha Duraibabu, CPA, MBA as Senior Vice President and Chief Financial Officer, effective June 1, 2021. Ms. Duraibabu will lead all financial activities and report to the Chief Executive Officer. "Prathyusha has served as our Principal Accounting Officer for nearly two years and has contributed significantly to Sangamo with her wealth of experience and proven track record in optimizing financial strategy and operations, driving organizational change, and building diverse teams," said Sandy Macrae, Chief Executive Officer of Sangamo. "I look forward to Prathyusha's leadership and sa

      5/24/21 4:15:00 PM ET
      $SGMO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $SGMO
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Sangamo Therapeutics Inc.

      SC 13G/A - SANGAMO THERAPEUTICS, INC (0001001233) (Subject)

      11/12/24 4:53:35 PM ET
      $SGMO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Sangamo Therapeutics Inc.

      SC 13G/A - SANGAMO THERAPEUTICS, INC (0001001233) (Subject)

      11/4/24 1:54:32 PM ET
      $SGMO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Sangamo Therapeutics Inc.

      SC 13G/A - SANGAMO THERAPEUTICS, INC (0001001233) (Subject)

      8/16/24 6:40:25 PM ET
      $SGMO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care